{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:10:32Z","timestamp":1765609832410,"version":"3.41.0"},"reference-count":31,"publisher":"Asia Pacific Academy of Ophthalmology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia Pac J Ophthalmol (Phila)"],"published-print":{"date-parts":[[2019]]},"DOI":"10.22608\/apo.2017495","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T03:40:34Z","timestamp":1518493234000},"source":"Crossref","is-referenced-by-count":12,"title":["Anti-VEGF Agents and the Risk of Arteriothrombotic Events"],"prefix":"10.22608","member":"9895","published-online":{"date-parts":[[2019]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","unstructured":"1. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788\u20121795.","journal-title":"Br J Cancer"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMra061889","article-title":"Coronary microvascular dysfunction","volume":"356","author":"PG","year":"2007","unstructured":"2. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356:830\u2012840.","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2415-12-11","article-title":"Hospitalized cardiovascular events in patients with diabetic macular edema","volume":"12","author":"Nguyen-Khoa","year":"2012","unstructured":"3. Nguyen-Khoa BA, Goehring EL, Werther W, et al. Hospitalized cardiovascular events in patients with diabetic macular edema. BMC Ophthalmol. 2012;12:11.","journal-title":"BMC Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis","volume":"134","author":"RL","year":"2016","unstructured":"4. Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016;134:21\u201229.","journal-title":"JAMA Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","unstructured":"5. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789\u2012801.","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","unstructured":"6. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247\u20122254.","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/jamaophthalmol.2017.0455","article-title":"Vascular safety of ranibizumab in patients with diabetic macular edema: a pooled analysis of patient-level data from randomized clinical trials","volume":"135","author":"Zarbin","year":"2017","unstructured":"7. Zarbin MA, Dunger-Baldauf C, Haskova Z, et al. Vascular safety of ranibizumab in patients with diabetic macular edema: a pooled analysis of patient-level data from randomized clinical trials. JAMA Ophthalmol. 2017;135:424\u2012431.","journal-title":"JAMA Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ophtha.2011.09.044","article-title":"Age-related macular degeneration and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis","volume":"119","author":"Fernandez","year":"2012","unstructured":"8. Fernandez AB, Wong TY, Klein R, et al. Age-related macular degeneration and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Ophthalmology. 2012;119:765\u2012770.","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.14423\/SMJ.0000000000000329","article-title":"Age-related macular degeneration and coronary artery disease in a VA population.","volume":"108","author":"Thomas","year":"2015","unstructured":"9. Thomas J, Mohammad S, Charnigo R, et al. Age-related macular degeneration and coronary artery disease in a VA population. South Med J. 2015;108:502\u2012506.","journal-title":"South Med J","ISSN":"https:\/\/id.crossref.org\/issn\/0038-4348","issn-type":"print"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/bjo.2007.131706","article-title":"Age-related macular degeneration and mortality from cardiovascular disease or stroke","volume":"92","author":"Tan","year":"2008","unstructured":"10. Tan JS, Wang JJ, Liew G, et al. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol. 2008;92:509\u2012512.","journal-title":"Br J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1161\/STROKEAHA.112.654632","article-title":"Age-related macular degeneration and long-term risk of stroke subtypes","volume":"43","author":"Ikram","year":"2012","unstructured":"11. Ikram MK, Mitchell P, Klein R, et al. Age-related macular degeneration and long-term risk of stroke subtypes. Stroke. 2012;43:1681\u20121683.","journal-title":"Stroke"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1161\/STROKEAHA.111.616359","article-title":"Age-related macular degeneration and the risk of stroke: the Rotterdam Study","volume":"42","author":"Wieberdink","year":"2011","unstructured":"12. Wieberdink RG, Ho L, Ikram MK, et al. Age-related macular degeneration and the risk of stroke: the Rotterdam Study. Stroke. 2011;42:2138\u20122142.","journal-title":"Stroke"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/STROKEAHA.109.571000","article-title":"Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study","volume":"41","author":"CC","year":"2010","unstructured":"13. Hu CC, Ho JD, Lin HC. Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study. Stroke. 2010;41:613\u2012617.","journal-title":"Stroke"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","unstructured":"14. Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636\u20121641.","journal-title":"Br J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ajo.2014.06.009","article-title":"Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.","volume":"158","author":"Wang","year":"2014","unstructured":"15. Wang X, Sawada T, Sawada O, et al. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol. 2014;158:738\u2012744.e731.","journal-title":"Am J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9394","issn-type":"print"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.","volume":"90","author":"Carneiro","year":"2012","unstructured":"16. Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90:e25\u2012e30.","journal-title":"Acta Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/1755-375X","issn-type":"print"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00417-014-2717-0","article-title":"Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration","volume":"252","author":"Yoshida","year":"2014","unstructured":"17. Yoshida I, Shiba T, Taniguchi H, et al. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2014;252:1483\u20121489.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1136\/bjophthalmol-2012-302451","article-title":"Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema","volume":"97","author":"Zehetner","year":"2013","unstructured":"18. Zehetner C, Kirchmair R, Huber S, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97:454\u2012459.","journal-title":"Br J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/aos.12604","article-title":"Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.","volume":"93","author":"Zehetner","year":"2015","unstructured":"19. Zehetner C, Kralinger MT, Modi YS, et al. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol. 2015;93:e154\u2012e159.","journal-title":"Acta Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/1755-375X","issn-type":"print"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1097\/IAE.0b013e31825db6ba","article-title":"Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials","volume":"32","author":"Bressler","year":"2012","unstructured":"20. Bressler NM, Boyer DS, Williams DF, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina. 2012;32:1821\u20121828.","journal-title":"Retina"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","article-title":"Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis","volume":"132","author":"Thulliez","year":"2014","unstructured":"21. Thulliez M, Angoulvant D, Le Lez ML, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014;132:1317\u20121326.","journal-title":"JAMA Ophthalmol"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"5. Ueta T, Noda Y, Toyama T, et al. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials. Ophthalmology. 2014;121:2193\u20122203.e2191\u2012e2197.","DOI":"10.1016\/j.ophtha.2014.05.022"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e4203","DOI":"10.1136\/bmj.e4203","article-title":"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested casecontrol study.","volume":"345","author":"Campbell","year":"2012","unstructured":"23. Campbell RJ, Gill SS, Bronskill SE, et al. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested casecontrol study. BMJ. 2012;345:e4203.","journal-title":"BMJ","ISSN":"https:\/\/id.crossref.org\/issn\/0959-8138","issn-type":"print"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","unstructured":"24. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128:1273\u20121279.","journal-title":"Arch Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","unstructured":"25. Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37:1847\u20121858.","journal-title":"Retina"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","unstructured":"26. Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54:1616\u20121624.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1074\/jbc.M110.164848","article-title":"Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain","volume":"286","author":"Andersen","year":"2011","unstructured":"27. Andersen JT, Pehrson R, Tolmachev V, et al. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem. 2011;286:5234\u20125241.","journal-title":"J Biol Chem"},{"key":"ref27","first-page":"2803","article-title":"FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.","volume":"15","author":"Kim","year":"2009","unstructured":"28. Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis. 2009;15:2803\u20122812.","journal-title":"Mol Vis","ISSN":"https:\/\/id.crossref.org\/issn\/1090-0535","issn-type":"print"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1167\/iovs.13-12574","article-title":"Expression of neonatal Fc receptor in the eye","volume":"55","author":"Powner","year":"2014","unstructured":"29. Powner MB, McKenzie JA, Christianson GJ, et al. Expression of neonatal Fc receptor in the eye. Invest Ophthalmol Vis Sci. 2014;55:1607\u20121615.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: oneyear findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","unstructured":"30. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: oneyear findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399\u20121411.","journal-title":"Ophthalmology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e96402","DOI":"10.1371\/journal.pone.0096402","article-title":"Control of angiogenesis by galectins involves the release of platelet-derived proangiogenic factors.","volume":"9","author":"Etulain","year":"2014","unstructured":"31. Etulain J, Negrotto S, Tribulatti MV, et al. Control of angiogenesis by galectins involves the release of platelet-derived proangiogenic factors. PLoS One. 2014;9:e96402.","journal-title":"PLoS One","ISSN":"https:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:08:47Z","timestamp":1751396927000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/apjoo\/Fulltext\/2018\/01000\/Anti_VEGF_Agents_and_the_Risk_of_Arteriothrombotic.11.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":31,"URL":"https:\/\/doi.org\/10.22608\/apo.2017495","relation":{},"ISSN":["2162-0989","2162-0989"],"issn-type":[{"type":"print","value":"2162-0989"},{"type":"electronic","value":"2162-0989"}],"subject":[],"published":{"date-parts":[[2019]]}}}